Login to Your Account



Other News To Note


Friday, October 12, 2012
• Agios Pharmaceuticals Inc., of Cambridge, Mass., said a recent publication highlighted the discovery of the first potent inhibitors of mutant isocitrate dehydrogenase (IDH) that lower tumor 2-HG in vivo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription